Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.62 |
| ▸ | KIT | P10721 | 3/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | WHR1 | P49842 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 3/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KRAS | P01116 | 1/20 | 0.49 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4782102 | 0.88 | WHR1 (0.61) | EGFRKITRETKDRWHR1 | |
| SCHEMBL6181412 | 0.83 | EGFR (0.63) | EGFRKITRETKDRWHR1 | |
| SCHEMBL6182383 | 0.82 | EGFR (0.56) | EGFRKITRETKDRCSF1R | |
| SCHEMBL4725258 | 0.80 | KDM1A (0.57) | EGFRKITRETKDRWHR1 | |
| SCHEMBL27436541 | 0.80 | KIT (0.52) | EGFRKITRETKDRCSF1R | |
| SCHEMBL1264612 | 0.78 | KIT (0.60) | EGFRKITKDRCSF1RLCK | |
| SCHEMBL8709390 | 0.77 | EGFR (0.67) | EGFRKITKDRLCKPDGFRB | |
| SCHEMBL4725216 | 0.77 | EGFR (0.58) | EGFRKITRETKDRWHR1 | |
| SCHEMBL4727998 | 0.77 | EGFR (0.58) | EGFRKITRETKDRWHR1 | |
| Hydrochloric Acid SCHEMBL8503409 | 0.76 | EGFR (0.67) | EGFRKITKDRLCKKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | CSF1R, CSF3R, FLT3 | EGFR 628/4885KIT 24/4885RET 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.